Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-26T13:15:07.015Z Has data issue: false hasContentIssue false

Chapter 30 - Hyperprolactinemia*

from Section V - Reproductive endocrinology and infertility

Published online by Cambridge University Press:  05 May 2016

By
Jessica T. Servey
Edited by
Martin Olsen  and
Botros Rizk
Martin Olsen
Affiliation:
East Tennessee State University
Botros Rizk
Affiliation:
University of South Alabama
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Office Care of Women , pp. 331 - 340
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Molitch, ME. Prolactinoma. In: Melmed, S, ed. The Pituitary, 3rd ed. Waltham, MA: Academic Press; 2011: 475–531.Google Scholar
Melmed, S, Casanueva, FF, Hoffman, AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273–88.CrossRefGoogle ScholarPubMed
Waldstreicher, J, Duffy, JF, Brown, EN, et al. Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep independent circadian rhythm of circulation PRL levels – a clinical research center study. J Clin Endocrinol Metab. 1996;81:1483–7.Google Scholar
Daly, AF, Rixhon, M, Adam, C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.CrossRefGoogle ScholarPubMed
Fernandez, A, Karavitaki, N, Wass, JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–82.CrossRefGoogle ScholarPubMed
Kars, M, Souverein, PC, Herings, RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94:2729–34.CrossRefGoogle ScholarPubMed
Thirunavakkarasu, K, Dutta, P, Sridhar, S, et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013 Dec;44(3):750–5.CrossRefGoogle ScholarPubMed
Molitch, ME, Reichlin, S. Hyperprolactinemic disorders. Dis Mon. 1982;28:1–58.CrossRefGoogle ScholarPubMed
Schlechte, J, Sherman, B, Halmi, N, et al. Prolactin secreting pituitary tumours in amenorrheic women: a comprehensive study. Endocr Rev. 1980;1:295–308.CrossRefGoogle ScholarPubMed
Lee, D, Oh, Y, Yoon, B, et al. Prevalence of hyperprolactinemia in adolescents and young women with menstruation related problems. Am J Obstet Gyneco. 2012;206:213 e1–5.CrossRefGoogle Scholar
Demura, R, Ono, M, Demura, H, et al. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. J Clin Endocrinol Metab. 1982;54:1246–50.CrossRefGoogle ScholarPubMed
Prabhakar, VK, Davis, JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):341–53.CrossRefGoogle ScholarPubMed
Sobrinho, LG. Emotional aspects of hyperprolactinaemia. Psychother Psychosom. 1998;67:133–9.CrossRefGoogle Scholar
Melen, O. Neuro-ophthalmologic features of pituitary tumors. Endocrinol Metab Clin North Am. 1987;16:585–608.CrossRefGoogle ScholarPubMed
Cottier, JP, Destrieux, C, Brunereau, L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000;215:463–9.CrossRefGoogle ScholarPubMed
Shimon, MD, Bronstein, J, Shapiro, G, et al. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47(3):889–94. First online 8 April 2014.CrossRefGoogle ScholarPubMed
Maor, Y, Berezin, M. Hyperprolactinemia in postmenopausal women. Fertil Steril. 1997;67:693–6.CrossRefGoogle ScholarPubMed
Delgrange, E, Raverot, G, Bex, M, et al. Giant prolactinomas in women. Eur J Endocrinol. 2013 Nov 22;170(1):31–8.Google ScholarPubMed
Schlechte, J, el-Khoury, G, Kathol, M, Walkner, L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1987;64:1021–6.CrossRefGoogle ScholarPubMed
Jarrell, J, Franks, S, McInnes, R, et al. Breast examination does not elevate serum prolactin. Fertil Steril. 1980;33:49–51.CrossRefGoogle Scholar
Luef, G. Horrmonal alterations following seizures. Epilepsy Behav. 2010 Oct;19(2):131–3.CrossRefGoogle ScholarPubMed
Bracero, N, Zacur, HA, Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am. 2001;28:77–84.CrossRefGoogle ScholarPubMed
Prosser, PR, Karam, JH, Townsend, JJ, Forsham, PH. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. Ann Intern Med. 1979;91(1):41–4.CrossRefGoogle ScholarPubMed
Schlechte, J, Dolan, K, Sherman, B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989;68:412–8.CrossRefGoogle ScholarPubMed
Sisam, DA, Sheehan, JP, Sheeler, LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987;48:67–71.CrossRefGoogle ScholarPubMed
Jeffcoate, WJ, Pound, N, Sturrock, ND, Lambourne, J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1996;45:299–303.CrossRefGoogle ScholarPubMed
Karunakaran, S, Page, RC, Wass, JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001;54:295–300.CrossRefGoogle ScholarPubMed
Sarwar, KN, Huda, MS, Van de Velde, V, et al. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013 Jun;98(6):2362–7.CrossRefGoogle ScholarPubMed
DailyMed. Bromocriptine. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f. Accessed 8 July 2014.Google Scholar
Webster, J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–38.Google ScholarPubMed
Wass, JA, Thorner, MO, Besser, GM. Letter: digital vasospasm with bromocriptine. Lancet. 1976;1:1135.CrossRefGoogle ScholarPubMed
Turner, TH, Cookson, JC, Wass, JA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed). 1984;289:1101–3.CrossRefGoogle ScholarPubMed
Molitch, ME, Elton, RL, Blackwell, RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.CrossRefGoogle ScholarPubMed
Wang, AT, Mullan, RJ, Lane, MA, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.CrossRefGoogle ScholarPubMed
DailyMed. Cabergoline. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e563bf14-daca-9bfb-f324-1d243150528e. Accessed 8 July 2014.Google Scholar
Webster, J, Piscitelli, G, Polli, A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study: European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf). 1993 Sep;39(3):323–9.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Landi, ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–52.Google ScholarPubMed
Delgrange, E, Daems, T, Verhelst, J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–52.CrossRefGoogle Scholar
Ono, M, Miki, N, Kawamata, T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721–7.CrossRefGoogle ScholarPubMed
Webster, J, Piscitelli, G, Polli, A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea: Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904–9.CrossRefGoogle ScholarPubMed
Nunes, V, El Dib, R, Boguszewski, C, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011:14;3:259–65.Google Scholar
Zanettini, R, Antonini, A, Gatto, G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39.CrossRefGoogle ScholarPubMed
Rasmussen, VG, Østergaard, K, Dupont, E, Poulsen, SH. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord. 2011 Apr;26(5):801–6.CrossRefGoogle ScholarPubMed
Kars, M, Delgado, V, Holman, ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348–56.CrossRefGoogle ScholarPubMed
Colao, A, Galderisi, M, Di Sarno, A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777–84.CrossRefGoogle ScholarPubMed
Halperin, I, Aller, J, Varela, C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf). 2012 Aug;77(2):275–80.CrossRefGoogle ScholarPubMed
Tan, T, Cabrita, IZ, Hensman, D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010 Sep;73(3):369–74.CrossRefGoogle ScholarPubMed
Vallette, S, Serri, K, Rivera, J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153–7.CrossRefGoogle Scholar
Auriemma, RS, Pivonello, R, Perone, Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013 Aug 28;169(3):359–66.CrossRefGoogle ScholarPubMed
Delgado, V, Biermasz, NR, van Thiel, SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012 Jul;77(1):99–105.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Sarnacchiaro, F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–83.Google ScholarPubMed
Biswas, M, Smith, J, Jadon, D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63:26–31.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Cappabianca, P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33.CrossRefGoogle ScholarPubMed
Kharlip, J, Salvatori, R, Yenokyan, G, Wand, GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94:2428–36.CrossRefGoogle ScholarPubMed
Anagnostis, P, Adamidou, F, Polyzos, SA, et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012 Mar;15(1):25–9.CrossRefGoogle ScholarPubMed
Moraes, AB, Silva, CM, Vieira Neto, L, et al. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013 Oct;79(4):447–56.CrossRefGoogle ScholarPubMed
Wu, ZB, Su, ZP, Wu, JS, et al. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary. 2008;11:63–70.CrossRefGoogle Scholar
Delgrange, E, Duprez, T, Maiter, D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf). 2006;64:456–62.CrossRefGoogle ScholarPubMed
Faria, MA, Tindall, GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg. 1982;56:33–43.CrossRefGoogle ScholarPubMed
Thomson, JA, Davies, DL, McLaren, EH, et al. Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ. 1994;309:1409–10.CrossRefGoogle ScholarPubMed
Ikeda, H, Watanabe, K, Tominaga, T, Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013 Sep;115(9):1621–5.CrossRefGoogle ScholarPubMed
Buchfelder, M, Schlaffer, S. Surgical treatment of pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):677–92.CrossRefGoogle Scholar
Sun, DQ, Cheng, JJ, Frazier, JL, et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2011;34:181–9.CrossRefGoogle Scholar
Rigg, LA, Lein, A, Yen, SS. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol. 1977;129:454–6.CrossRefGoogle ScholarPubMed
Glezer, A, Bronstein, M. Prolactinomas, cabergoline and pregnancy. Endocrine. 2014;47:64–9.CrossRefGoogle ScholarPubMed
Krupp, P, Monka, C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65:823–7.CrossRefGoogle ScholarPubMed
Molitch, ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011 Dec;25(6):885–96.CrossRefGoogle ScholarPubMed
Lebbe, M, Hubinont, C, Bernard, P, et al. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol. 2010;73:236–42.CrossRefGoogle ScholarPubMed
Webster, J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–38.Google ScholarPubMed
Colao, A, Abs, R, Barcena, DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008;68:66–71.CrossRefGoogle ScholarPubMed
Raymond, JP, Goldstein, E, Konopka, P, et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res. 1985;22:239–46.CrossRefGoogle ScholarPubMed
Konopka, P, Raymond, JP, Merceron, RE, et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146:935–8.CrossRefGoogle ScholarPubMed
Hurault-Delarue, C, Montastruc, J-L, Beau, A-B, et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;23(6):586–94.Google Scholar
Domingue, ME, Devuyst, F, Alexopoulou, O, et al. Outcome of prolactinoma after pregnancy and lactation: a study of 73 patients. Clin Endocrinol (Oxf). 2014 May;80(5):642–8.CrossRefGoogle ScholarPubMed
TOXNET databases. LactMed: Cabergoline. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs±lactmed:@or±%28@na±%22CABERGOLINE%22±%29. Accessed 8 July 2014.Google Scholar
TOXNET databases. LactMed: Bromocriptine. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs±lactmed:@term±@na±Bromocriptine. Accessed 8 July 2014.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×